An update on antenatal screening for Down's syndrome and specific implications for assisted reproduction pregnancies

  • Weisz B
  • Rodeck C
  • 18


    Mendeley users who have this article in their library.
  • 24


    Citations of this article.


Since the introduction of antenatal serum screening for Down's syndrome (DS) more than two decades ago, several screening approaches have been utilized in routine clinical practice. The current DS screening strategies involve mid-trimester serum biochemistry tests, first trimester tests combining sonographic markers and serum biochemistry and integration of first and second trimester markers. In this review, we evaluate the performance of DS screening strategies according to the Serum, Urine and Ultrasound Screening Study (SURUSS), the First and Second Trimester Evaluation of Risks (FASTER) Trial and the Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study. We also evaluate the performance of first trimester screening in studies and meta-analyses by other groups. Specific issues related to assisted reproduction technology (ART) pregnancies are also addressed in this review.

Author-supplied keywords

  • Down's syndrome
  • Integrated screening
  • Nuchal translucency
  • Screening

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Boaz Weisz

  • Charles H. Rodeck

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free